Safety and virologic effect of the HIV-1 broadly neutralizing antibodies, VRC01LS or VRC07-523LS, administered to HIV-infected adults in a phase 1 clinical trialG. Chen,E. Coates, C. Fichtenbaum,S. Koletar,R. Landovitz, R. Presti,T. Overton,J. Santana, R. S. Rothwel, J. Roa, E. Donaghy, L. Holman,L. Novik, N. Berkowitz,B. Larkin, M. Conan-Cibotti, R. Tressler,J. Wang,Z. Hu,E. Capparelli, F. Arnold, R. Bailer,A. McDermott, L. Gama, B. Graham, R. Koup,J. Mascola, J. Ledgerwood,P. TebasJOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2019）引用 5|浏览12暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
